Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06142396RecruitingEarly Phase 1
Dara-CyBorD for New Multiple Myeloma with Kidney Failure
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
Augusta, GeorgiaAges 18–80 - NCT05879757Recruiting
Real-world HyQvia use for adults with myeloma and weak immunity
This study looks at how HyQvia (an immune-boosting medicine given under the skin) is used in real life for adults with multiple myeloma and secondary immune problems. It may help doctors understand what works best and how patients do when HyQvia is used routinely.
CórdobaAges 18 years+ - NCT05519085RecruitingPhase 3
Test mezigdomide vs pomalidomide with standard drugs for myeloma
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
Los Alamitos, CaliforniaAges 18 years+ - NCT04240054RecruitingPhase 2
Study drugs before transplant for myeloma with kidney problems
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
Milwaukee, WisconsinAges 18 years+ - NCT07085728RecruitingPhase 2
Comparing two drug combinations for newly diagnosed multiple myeloma with kidney failure
This trial tests a new combination of drugs (daratumumab, bortezomib, and dexamethasone) against the usual combination (cyclophosphamide, bortezomib, and dexamethasone) in people with newly diagnosed multiple myeloma who also have kidney failure. The goal is to see if the new combination works better and helps protect kidney function.
Anchorage, AlaskaAges 18 years+ - NCT06932562RecruitingPhase 3
Testing linvoseltamab vs standard care for myeloma patients not eligible for transplant
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
AdelaideAges 18 years+ - NCT05243797RecruitingPhase 3
Teclistamab plus lenalidomide maintenance after transplant
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Phoenix, ArizonaAges 18 years+ - NCT07107529RecruitingPhase 2
Study of daratumumab with teclistamab or talquetamab for frail patients with newly diagnosed multiple myeloma
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
Ascoli PicenoAges 18 years+ - NCT07851493Recruiting
Exercise assessment before chemotherapy for multiple myeloma
This study looks at how exercise affects the body before you start chemotherapy for multiple myeloma. It aims to understand your fitness level to help tailor treatment support.
Munich, BavariaAges 18–99 - NCT07771803RecruitingEarly Phase 1
Soursop tea study for advanced blood cancer
This study tests whether drinking soursop tea can help people with advanced acute myeloid leukemia (AML) or multiple myeloma (MM) when other treatments have stopped working. It aims to see if the tea is safe and can reduce signs of the disease.
Camden, New JerseyAges 18 years+ - NCT07764978RecruitingPhase 3
New drug combo for multiple myeloma without stem cell transplant
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT07623798RecruitingPhase 3
Testing IBI3003 for relapsed or refractory multiple myeloma
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05203003Recruiting
Testing whether measurable cancer leftovers predict outcomes
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
ParisAges 18 years+ - NCT07509086RecruitingPhase 2
Enhanced CAR-T therapy for relapsed multiple myeloma
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
Changchun, JilinAges 18–80 - NCT06767254Recruiting
Using AI to predict early return of multiple myeloma
This study uses artificial intelligence to analyze how multiple myeloma may lead to early relapse. It may help doctors better predict and manage the disease.
Meldola, Forlì-CesenaAges 18 years+ - NCT05759793RecruitingPhase 1
CAR T trial for relapsed myeloma targeting GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
ShanghaiAges 18–75 - NCT06228794Recruiting
CPC blood test to predict multiple myeloma outcomes
This trial is studying a new blood test that measures circulating plasma cells (CPCs) to help predict how multiple myeloma may progress. It is for people newly diagnosed with multiple myeloma who have not yet started treatment.
Wuhan, HubeiAges 18–80 - NCT07045909RecruitingPhase 2
CAR-T cell therapy for newly diagnosed multiple myeloma
This trial tests an investigational CAR-T cell therapy (anitocabtagene autoleucel) in people with newly diagnosed multiple myeloma. It aims to see if this treatment is safe and effective when given after a short course of standard chemotherapy.
BadalonaAges 18–80 - NCT05219721RecruitingPhase 1
CAR T-cell study for relapsed multiple myeloma with GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
Wuhan, HubeiAges 18–75 - NCT06793475Recruiting
Aponermin before CAR-T for multiple myeloma with extramedullary disease
This trial tests whether a drug called aponermin, given before CAR-T cell therapy, can help people with multiple myeloma that has come back or not responded to treatment and has spread to soft tissues (extramedullary disease). The goal is to make the CAR-T therapy work better.
BeijingAges 18 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Birmingham, AlabamaAges 18 years+ - NCT05927571RecruitingPhase 1
Cevostamab and elranatamab combination study for relapsed myeloma
This Phase 1 trial tests whether combining two targeted antibody medicines—cevostamab and elranatamab—is safe and whether it shows signs of activity in people whose multiple myeloma has come back or not responded. It’s early-stage, so the main goal is safety, dosing, and how the medicines behave in the body.
Camperdown, New South WalesAges 18 years+ - NCT05020236RecruitingPhase 3
Elranatamab with daratumumab for previously treated myeloma
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
Clovis, CaliforniaAges 18 years+ - NCT04888039Recruiting
Living with myeloma follow-up study in West-Occitanie
This study follows people with symptomatic multiple myeloma who live in the West-Occitanie region. It aims to better understand patients’ experiences and needs over time, which may help improve care and support.
Toulouse, West-OccitanieAges 18 years+
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 540 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.